Sino Biopharmaceutical ( (HK:1177) ) has provided an update.

Sino Biopharmaceutical has formed a strategic joint venture with Indonesian healthcare group PT Tempo Scan Pacific Tbk to expand access to innovative medicines in Indonesia. The new entity, PT Tempo CTTQ Biopharmaceutical Indonesia, will leverage Sino Biopharmaceutical’s R&D and product pipeline alongside Tempo Scan’s nationwide manufacturing, regulatory and distribution platform.

The joint venture, in which Sino Biopharmaceutical holds a 51% stake, will focus on regulatory approvals, clinical trials, market entry and commercialization of specialty pharmaceutical products, with potential for future local manufacturing. By targeting Indonesia’s fast-growing pharmaceutical market, supported by universal healthcare expansion and rising demand for innovative therapies, the partnership aims to strengthen Sino Biopharmaceutical’s regional positioning while improving patient access across the country.

The most recent analyst rating on (HK:1177) stock is a Buy
with a HK$7.80 price target.
To see the full list of analyst forecasts on Sino Biopharmaceutical stock,
see the HK:1177 Stock Forecast page.